Abstract: The present invention relates to a deoxyribonucleic acid (DNA) comprising at least one promoter sequence, which is derived from a wild-type promoter of a methyltrophic yeast, whose transcription efficiency is modulated in comparison to the efficiency of the wild-type promoter by inserting or modifying a DNA binding site. The invention also relates to host cells, expression vectors, kits and methods for producing proteins while using the inventive DNA, as well as to different uses of the same and to a method for producing expression vectors.

Abstract: The invention relates to a nucleic acid molecule, comprising a nucleic acid which codes for a polypeptide with chorismate mutase activity and derivatives thereof, whereby the derivatives have at least 10% of the chorismate mutase activity of the chorismate mutase, according to the identification number of the SEQ ID NO:2. The invention further relates to vectors containing nucleic acid molecules, to host cells comprising nucleic acid molecules and their use in methods for producing polypetides with chorismate mutase activity. The invention also relates to the polypeptides with chorismate mutase activity and antibodies which specifically recognize the same. In addition, the invention relates to methods for producing auxotrophic yeast strains using the nucleic acid molecules and to the preparation of the yeast strains.

Abstract: The invention relates to a method for synthesising one protein or several proteins in a host cell of the yeast genus Arxula and a nucleic acid molecule including a suitable promoter for this purpose. Moreover, this invention relates to an expression vector, a host cell and a kit as well as the use of these. Object of the invention is to make available a method for synthesising a protein in a yeast of the genus Arxula, with which higher protein quantities can be obtained.

Abstract: The present invention relates to a method of carrying out blood tests. The invention is based on the finding that clinico-chemical blood parameters can be determined using not only blood serum but also blood plasma. Therefore, freshly taken blood samples, which are mixed with at least one thrombin inhibitor, can be used for determining both clinico-chemical parameters and hematological parameters. The clinico-chemical parameters can thus be determined using blood plasma, a separation of coagulable components being not required any more.

Abstract: A process for the recombinant production of proteins in the yeast Hansenula comprises transforming Hansenula with an expression cassette which comprises the following structural elements encoded:L-A-P-GENwhereL is a leader sequence,A is an adaptor producing an alpha-helix structure,P is a processing signal andGEN is a structural gene for the required protein.